<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03417076</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-446</org_study_id>
    <nct_id>NCT03417076</nct_id>
  </id_info>
  <brief_title>Absolute Bioavailability Study With Bexagliflozin</brief_title>
  <official_title>A Phase 1, Single Center, Open-label, Single Period, Non-randomized Study to Determine the Absolute Bioavailability of Bexagliflozin Tablets Following a Single Oral Dose Co-administered With an Intravenous Microtracer Dose of 14C-Bexagliflozin in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the absolute bioavailability of bexagliflozin
      following a single oral dose co-administered with an intravenous dose.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">September 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 16, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>absolute bioavailability (Fp.o.) of bexagliflozin tablets</measure>
    <time_frame>Up to 48 hours</time_frame>
    <description>oral to IV ratio of dose-normalized AUC0-inf (area under the plasma concentration time curve extrapolated to infinity)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>Up to 3 days</time_frame>
    <description>adverse event as a measure of safety and tolerability of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Bexagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive a single oral dose of bexagliflozin tablets, 20 mg, followed by a single IV dosing of &lt; 30 ug 14C-bexagliflozin in 0.9% saline solution).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>Bexagliflozin tablets, 20 mg, and bexagliflozin by IV</description>
    <arm_group_label>Bexagliflozin</arm_group_label>
    <other_name>EGT0001442, EGT0001474</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2

          -  no nicotine and tobacco consumption in the past 3 months

          -  willing and able to be confined to the clinical research facility as required by the
             protocol

        Exclusion Criteria:

          -  clinically significant history of allergy to drugs or latex

          -  history of alcohol or drug dependence in the past 12 months.

          -  donation of a significant amount of blood in the past 2 months

          -  willing to use an adequate form of birth control during the study and for 90 days
             after discharge from clinic

          -  exposure to investigational drug in the past 30 days or 7 half-lives of the
             investigational drug, whichever is longer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason Freeman, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoyan Li, Ph.D.</last_name>
    <phone>617-726-7960</phone>
    <email>xli@ccib.mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaoayan Li, Ph.D.</last_name>
      <phone>617-716-7960</phone>
      <email>xli@ccib.mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

